



# ABAM CERTIFICATION EXAMINATION BLUEPRINT

CORE CONTENT AREAS	■	25% of test questions
	■	20% of test questions
	■	40% of test questions
	■	15% of test questions
<b>01</b>	<b>DEFINITIONS</b>	
01.01	Addiction	
01.02	Addiction Medicine	
01.03	Unhealthy Use	
01.04	Dependence	
01.05	Withdrawal	
01.06	Detoxification	
01.07	Substance-Related Disorders	
01.08	ICD10 Diagnostic Categories	
<b>02</b>	<b>GENETICS</b>	
02.01	Heritability of Risk for Addiction	
02.02	Epigenetic Phenomena Related to Addiction	
02.03	Genetic Predictors of Treatment Response	
<b>03</b>	<b>PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES</b>	
03.01	Drug Metabolism and Principles of Drug Interactions (Including the Impact of Addictive Drug Use on the Metabolism of Common Therapeutic Medications)	
03.02	Reinforcement	
03.03	Tolerance	
03.04	Cross-Tolerance	
03.05	Physical Dependence	
03.06	Conditioning	
03.07	Sensitization	
03.08	Impact of Route of Drug Administration (Oral, Sublingual, Intravenous, Inhalation, Intramuscular, etc.)	
<b>04</b>	<b>PHARMACOLOGY</b>	
04.01	Alcohol	
04.02	Benzodiazepines, Benzodiazepine Receptor Agonists, Barbiturates and Other Sedative-Hypnotics	
04.03	Opioids (Opium, Heroin, Prescription Opioids)	
04.04	Cocaine, Amphetamine and Other Stimulants	
04.05	Nicotine and Tobacco	
04.06	Cannabinoids	
04.07	Hallucinogens (LSD, Mescaline, Psilocybin, and Other Hallucinogens)	

04.08	Dissociatives (Phencyclidine, Ketamine, Dextromethorphan and Other Dissociatives)
04.09	Inhalants (Nitrous Oxide, Hydrocarbons and Other Inhalants)
04.10	Anabolic Steroids
04.11	Club Drugs (MDMA, GHB, and Other Club Drugs)
<b>05</b>	<b>NEUROBIOLOGY OF ADDICTION</b>
05.01	Animal Models of Addiction
05.02	Neuropharmacology
05.01	Animal Models of Addiction
05.02	Neuropharmacology
05.02.01	Acetylcholine
05.02.02	Norepinephrine
05.02.03	Dopamine
05.02.04	Serotonin
05.02.05	Gamma-Aminobutyric Acid (GABA)
05.02.06	Glutamate and NMDA Receptors
05.02.07	Other Amino Acids and Peptides
05.02.08	Endogenous Opioids
05.02.09	Endocannabinoids
05.03	Cellular and Molecular Mechanism in Addiction (Including Neuro-Adaptation, Epigenetic Phenomena, etc.)
05.04	Neuro-Imaging of Addiction and Related Phenomena (Craving, Relapse, Recovery, etc.)
<b>06</b>	<b>EPIDEMIOLOGICAL CONCEPTS</b>
06.01	Epidemiologic Associations and Interpretation
06.02	Biostatistics
06.02.01	Vital Statistics and Demography
06.02.02	Describing Data
06.02.03	Hypothesis Testing
06.02.04	Meta-Analysis
06.02.05	Measurements of Morbidity and Mortality
<b>07</b>	<b>EPIDEMIOLOGICAL TRENDS OF SUBSTANCE USE DISORDERS</b>
07.01	Incidence, Prevalence, and Initiation
07.02	Special Populations
07.02.01	Injury/Trauma
07.02.02	The Elderly
07.02.03	Women

07.02.04	Pregnant Women and Newborns
07.02.05	Adolescents and Young Adults
07.02.06	Families With Alcohol and Other Drug Using Members (Including Children at Risk)
07.03	Alcohol and Drug Use in the Workplace
07.03.01	General Trends and Operational Definitions of Use/Dependence in the Workplace
07.03.02	Adverse Effects
07.03.02.01	Absenteeism
07.03.02.02	Injury: Occupational and Non-Occupational
07.03.02.03	Implications for Health Care Utilization
07.03.03	Employee Assistance and Prevention Programs
07.03.04	Clinical and Legal Considerations in Drug Testing
07.03.04.01	Workplace Drug Testing
07.03.04.02	Medical Review Officer (MRO) Responsibilities and Authority
07.03.05	Fitness for Duty Evaluations
07.03.06	Substance Use Disorders in Health Professionals
07.03.06.01	Epidemiology
07.03.06.02	Intervention, Treatment and Monitoring
<b>08</b>	<b>PREVENTION</b>
08.01	Primary Prevention
08.02	Secondary Prevention
08.03	Tertiary Prevention
08.04	Environmental Interventions to Reduce Alcohol, Tobacco and Other Drug Use
08.05	Prevention Programs
08.05.01	High Risk Populations
08.05.02	Educational Approaches
08.05.03	Community Organizational Approaches
08.05.04	Public Policy Approaches
08.05.04.01	Regulation of Supply
08.05.04.02	Demand Reduction
<b>09</b>	<b>SCREENING, ASSESSMENT AND BRIEF INTERVENTION</b>
09.01	Screening
09.01.01	Laboratory Tests
09.01.01.01	Clinical Drug Testing
09.01.02	Standard Questionnaires
09.01.02.01	Adults
09.01.02.02	Adolescents
09.01.02.03	Pregnant Women
09.02	Assessment
09.03	Brief Intervention
09.03.01	Ambulatory Care Settings
09.03.01.01	Pregnant Outpatients
09.03.01.02	Adolescent Outpatients
09.03.02	Emergency Departments
09.03.03	Hospital Inpatient Settings

<b>10</b>	<b>OVERVIEW OF ADDICTION TREATMENT</b>
10.01	History of Addiction Medicine
10.02	Treatment of Alcohol Use Disorders
10.03	Treatment of Drug Use Disorders
10.04	Linking Addiction Treatment With Other Medical and Psychiatric Treatment
10.05	Alternative Therapies for Alcohol and Drug Addiction
10.06	Non-Substance Addictions: Gambling, Sex, Food
10.07	Treatment Needs of Children and Adolescents
10.08	Treatment Needs of Seniors
10.09	Quality Management in Addiction Treatment
10.09.01	Outcome Measurement
10.09.02	Satisfaction Measurement
10.09.03	Performance Evaluation
<b>11</b>	<b>MANAGEMENT OF INPATIENT AND OUTPATIENT INTOXICATION AND WITHDRAWAL</b>
11.01	General Principles in Management of Intoxication and Withdrawal
11.02	Management of Alcohol Intoxication and Withdrawal
11.03	Management of Sedative-Hypnotic Intoxication and Withdrawal
11.04	Management of Opioid Intoxication and Withdrawal
11.05	Management of Other Drug Intoxication and Withdrawal (e.g., Cocaine, Stimulants, Nicotine, Phencyclidine, Cannabinoids, Hallucinogens, Dissociatives, Inhalants, Steroids, Club Drugs, etc.)
11.06	Pharmacologic and Non-Pharmacologic Intervention for Neonatal Intoxication and Withdrawal for Opioids and Sedatives
11.07	Management of Adverse Impact and Long-Term Consequences of Alcohol on the Fetus
11.08	Management of Alcohol and Drug Withdrawal Among Those Hospitalized for an Acute Co-Morbid Condition (Including Critical Care Detoxification)
<b>12</b>	<b>PHARMACOLOGIC INTERVENTIONS FOR ADDICTIONS</b>
12.01	Pharmacological Interventions for Opioid Dependence
12.02	Pharmacological Interventions for Alcohol Dependence
12.03	Pharmacological Interventions for Tobacco Dependence
12.04	Pharmacologic Interventions for Other Drug Dependence
12.05	Pharmacologic and Non-Pharmacologic Interventions for Neonatal Intoxication and Withdrawal for Opioids and Sedatives
12.06	Pharmacological Interventions for Non-Substance Related Addictions
<b>13</b>	<b>BEHAVIORAL INTERVENTIONS</b>
13.01	Psychological Aspects of Alcohol and drug Use, Intoxication and Addiction (Including "Set and Setting," Placebo and Expectation)

13.02	Patient Engagement and Securing Treatment Entry
13.03	Motivating Patients to Change
13.04	Individual Psychotherapy
13.05	Cognitive Behavioral Therapy
13.05.01	Relapse Prevention
13.05.02	Community Reinforcement and Vouchers
13.05.03	Contingency Management
13.05.04	Matrix Model
13.06	Group Therapy
13.07	Self-Help Groups
13.07.01	Twelve-Step programs and 12-Step Facilitation Therapies
13.07.02	Other Self-Help Programs
13.08	Couples and Family Counseling, Therapies and Interventions
13.09	Adolescent Relapse Prevention
13.10	Residential Treatment and Therapeutic Communities
13.11	Treatment Retention and Chronic Disease Management
13.12	Comprehensive Case Management (Use of Integrated Medical Care and Supplemental Services for Persons with Chronic, Persistent Addiction)
13.13	Translating Research to Practice
13.14	Principles of Integrating Behavioral and Pharmacological Treatment
13.15	ASAM Patient Placement Criteria and Appropriate Use of Levels of Care
<b>14</b>	<b>CO-OCCURRING AND MEDICAL DISORDERS AMONG PATIENTS WITH ALCOHOL AND OTHER DRUG USE AND ADDICTION</b>
14.01	General Medical Evaluation and Management
14.02	General Medical and Surgical Complications
14.02.01	Cardiovascular Consequences
14.02.02	Hepatic Disorders
14.02.03	Other Gastrointestinal Disorders
14.02.04	Renal and Metabolic Disorders
14.02.05	Respiratory Disorders
14.02.06	Neurological Disorders
14.02.07	Infectious Diseases (HIV, TB, Sexually Transmitted Infections and Others)
14.02.08	Hematologic Disorders
14.02.09	Sleep Disorders
14.02.10	Acute Traumatic Injuries
14.02.11	Rehabilitation From Traumatic Brain Injuries and Spinal Cord Injuries
14.02.12	Terminal Illness, Palliative medicine and End-of-Life Issues
14.02.13	Endocrine and Reproductive Disorders
14.03	Obstetrical Complications and Pregnancy-Related Disorders and Complications
14.04	Drug Exposure, Including Fetal Alcohol Spectrum Disorders

<b>15</b>	<b>CO-OCCURRING PSYCHIATRIC DISORDERS AMONG PATIENTS WITH ALCOHOL AND OTHER DRUG USE AND ADDICTION</b>
15.01	Neuropsychological Dysfunction (Problems With Attention, Memory, Learning, Executive Function)
15.02	Substance-Induced Mental Disorders
15.03	Affective Disorders
15.04	Posttraumatic Stress Disorder
15.05	Other Anxiety Disorders
15.06	Psychotic Disorders
15.07	Attention Deficit/Hyperactivity Disorder
15.08	Eating Disorders
15.09	Personality Disorders
15.10	Cognitive and Behavioral Diagnoses Secondary to In-Utero Alcohol and Drug Exposure
<b>16</b>	<b>PAIN AND ADDICTION</b>
16.01	Musculoskeletal and Orthopedic Problems
16.02	Chronic Non-Cancer Pain and Addiction
16.03	Psychological Issues in the Management of Pain
16.04	Non-Opioid Treatments in the Management of Pain
16.05	Opioid Treatments in the Management of Pain
16.06	Legal and Regulatory Considerations in Pain Management
<b>17</b>	<b>ETHICAL, LEGAL AND LIABILITY ISSUES IN ADDICTION PRACTICE</b>
17.01	Ethical issues in Addiction Practice
17.02	Informed Consent and Confidentiality in Clinical Practice and Clinical Research
17.03	Clinical and Legal Considerations in Prescribing Drugs for Treatment of Addiction
17.04	Clinical and Legal Considerations in the Treatment of Minors
17.04.01	Adolescent School-Based Drug Testing
17.05	Drug Courts and the Treatment of Incarcerated Populations
17.06	Licensing and Credentialing Issues for Health Professionals
17.07	Forensic Addiction Medicine: Expert Witness and Civil Commitment
17.08	Competency and the Assessment of Competence
17.09	Environmental Tobacco Smoke
17.10	Disability and Substance Use
17.11	Americans With Disabilities Act (ADA)
17.12	Medical Futility and End-Stage Addiction
17.12.01	Therapeutic Pessimism/Nihilism and Pseudo-Futility
17.13	Addiction Services Administration